Together with ERCC4 (xeroderma pigmentosum group F, XPF), ERCC1 forms a structure-specific endonuclease which plays a rate-limiting role in the nucleotide excision (NER) pathway that recognizes and removes DNA adducts that are formed during cisplatin treatment. The gene discussed is ERCC4; the disease is xeroderma pigmentosum.